Role of IGF-I in Type 2 diabetes: a focus on the mouse model

References

• Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations. Diab. Vasc. Dis. Res.4(1), 13–19 (2007).
   PubMedGoogle Scholar
• Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am. J. Cardiol.68(1), 85–89 (1991).
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. Nephropathy in patients with Type 2 diabetes mellitus. N. Engl. J. Med.341(15), 1127–1133 (1999).
   PubMed Web of Science ®Google Scholar
• Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes38(9), 1077–1081 (1989).
   PubMed Web of Science ®Google Scholar
• Yang CW, Hattori M, Vlassara H et al. Overexpression of TGF-β1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in non-obese diabetic mice. J. Am. Soc. Nephrol.5(8), 1610–1617 (1995).
   PubMed Web of Science ®Google Scholar
• The DCCT Group. The effect of intensive insulin treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.3299(14), 977–986 (1993).
   Google Scholar
• Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N. Engl. J. Med.320(18), 1161–1165 (1989).
   PubMed Web of Science ®Google Scholar
• Doi T, Striker LJ, Quaife C et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin-like growth factor I. Am. J. Pathol.131(3), 398–403 (1988).
   PubMed Web of Science ®Google Scholar
• Yang CW, Striker LJ, Pesce C et al. Glomerulosclerosis and body growth are mediated by different portions of bovine growth hormone. Studies in transgenic mice. Lab. Invest.68(1), 62–70 (1993).
   Google Scholar
• El Nahas AM, Bassett AH, Cope GH. Role of growth hormone in the development of experimental renal scarring. Kidney Int.40(1), 29–34 (1991).
   Web of Science ®Google Scholar
• Flyvbjerg A, Marshall SM, Frystik J, Hansen KW, Harris AG, Orskov H. Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int.41(4), 805–812 (1992).
   PubMedGoogle Scholar
• Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat. Endocrinol.4(4), 199–203 (2005).
   PubMedGoogle Scholar
• Seigel GM, Lupien SB, Campbell LM, Ishii DN. Systemic IGF-I treatment inhibits cell death in diabetic rat retina. J. Diabetes Complications20(3), 196–204 (2006).
   PubMed Web of Science ®Google Scholar
• Blankestijn PJ, Derkx FHM, Birkenhager JC et al. Glomerular hyperfiltration in insulin dependent diabetes mellitus is correlated with enhanced growth hormone secretion. J. Clin. Endocrinol. Metab.77(2), 498–502 (1993).
   PubMed Web of Science ®Google Scholar
• Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N. Engl. J. Med.310(13), 810–815 (1984).
   PubMed Web of Science ®Google Scholar
• Chen NY, Chen WY, Kopchick JJ. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology137(11), 5163–5165 (1996).
   PubMed Web of Science ®Google Scholar
• Menon RK, Stephan DA, Rao RH et al. Tissue-specific regulation of the growth hormone receptor gene in streptozotocininduced diabetes in the rat. J. Endocrinol.142(3), 453–462 (1994).
   PubMed Web of Science ®Google Scholar
• Mercado M, Molitch ME, Bauman G. Low plasma growth hormone binding protein in IDDM. Diabetes41(5), 605–609 (1992).
   PubMedGoogle Scholar
• Landau D, Segev Y, Eshet R, Flyvbjerg A, Phillip M. Changes in the growth hormone–IGF-I axis in nonobese diabetic mice. Int. J. Exp. Diab. Res.1(1), 9–18 (2001).
   Google Scholar
• Landau D, Domene’ H, Flyvbjerg A et al. Differential renal growth hormone (GH) receptor and GH binding protein expression in experimental diabetes mellitus. Growth Horm. IGF Res.8(2), 39–45 (1998).
   Google Scholar
• Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M. Growth hormone receptor antagonism prevents early renal changes in the non-obese diabetic (NOD) mouse. J. Am. Soc. Nephrol.10(11), 2374–2381 (1999).
   PubMedGoogle Scholar
• Landau D, Israel E, Rivkis I et al. The effect of growth hormone on the development of diabetic kidney disease in rats. Nephrol. Dial. Transplant.18(4), 694–702 (2003).
   PubMedGoogle Scholar
• Segev Y, Landau D, Marbach M, Schadeh N, Flyvbjerg A, Phillip M. Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with renal accumulation of insulin-like growth factor (IGF) I. J. Am. Soc. Nephrol.8(3), 436–444 (1997).
   PubMed Web of Science ®Google Scholar
• Landau D, Chin E, Bondy C et al. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. Endocrinology136(5), 1835–1842 (1995).
   PubMedGoogle Scholar
• Cingel-Ristic V, Schrijvers BF, van Vliet AK et al. Kidney growth in normal and diabetic mice is not affected by human insulin-like growth factor binding protein-1 administration. Exp. Biol. Med. (Maywood)230(2), 135–143 (2005).
   Google Scholar
• Franek E, Schaefer F, Bergis K, Feneberg R, Ritz E. Abnormal pulsatile secretion of growth hormone in non-insulin-dependent diabetes mellitus. Clin. Endocrinol. (Oxford)47(4), 471–478 (1997).
   Google Scholar
• Bang P, Brismar K, Rosenfeld RG et al. Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulindependent diabetes mellitus versus healthy nonobese and obese subjects. J. Clin. Endocrinol. Metab.78(4), 960–967 (1994).
   PubMedGoogle Scholar
• Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev.25(6), 971–1010 (2004).
   PubMed Web of Science ®Google Scholar
• Kratzsch J, Keliner K, Zilkens T et al. Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus. Clin. Endocrinol. (Oxford)44(6), 673–678 (1996).
   Web of Science ®Google Scholar
• Ji S, Guan R, Frank SJ, Messina JL. Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway. J. Biol. Chem.274(19), 13434–13442 (1999).
   Google Scholar
• Uchida T, Nakamura T, Hashimoto N et al. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat. Med.11(2), 175–182 (2005).
   PubMed Web of Science ®Google Scholar
• van Haeften TW, Twickler TB. Insulin-like growth factors and pancreas β cells. Eur. J. Clin. Invest.34(4), 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• Heald AH, Siddals KW, Fraser W et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in Type 2 diabetes. Diabetes51(8), 2629–2636 (2002).
   PubMed Web of Science ®Google Scholar
• Franco C, Bengtsson BA, Johannsson G. Visceral obesity and the role of the somatotropic axis in the development of metabolic complications. Growth Horm. IGF Res.11, S97–S102 (2001).
   Google Scholar
• Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology147(6), 2754–2763 (2006).
   Google Scholar
• Johannsson G, Marin P, Lonn L et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab.82(3), 727–734 (1997).
   PubMed Web of Science ®Google Scholar
• Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J. Endocrinol. Invest.22(5), 41–46 (1999).
   Google Scholar
• Ha TS, Barnes JL, Stewart JL et al. Regulation of renal laminin in mice with Type II diabetes. J. Am. Soc. Nephrol.10(9), 1931–1939 (1999).
   Google Scholar
• Segev Y, Eshet R, Rivkis I et al. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease. Nephrol. Dial. Transplant.19(12), 3021–3028 (2004).
   PubMed Web of Science ®Google Scholar
• Segev Y, Eshet R, Yakir O, Haim N, Phillip M, Landau D. Systemic and renal GH–IGF-I axis involvement in a mouse model of Type II diabetes. Diabetologia.50(6), 1327–1334 (2007).
   Google Scholar
• Lee PD, Giudice LC, Conover CA et al. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med.216(3), 319–357 (1997).
   PubMed Web of Science ®Google Scholar
• Orland MJ, Permutt MA. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes36(3), 341–347 (1987).
   PubMedGoogle Scholar
• Schinner S, Scherbaum WA, Bornstein SR et al. Molecular mechanisms of insulin resistance. Diabet. Med.22(6), 674–682 (2005).
   PubMed Web of Science ®Google Scholar
• Tomizawa M, Kumar A, Perrot V et al. Insulin inhibits the activation of transcription by a C-terminal fragment of the forkhead transcription factor FKHR. A mechanism for insulin inhibition of insulin-like growth factor-binding protein-1 transcription. J. Biol. Chem.275(10), 7289–7295 (2000).
   Google Scholar
• Nakae J, Biggs WH 3rd, Kitamura T et al. Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet.32(2), 245–253 (2002).
   PubMed Web of Science ®Google Scholar
• Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol.20(23), 8969–8982 (2000).
   PubMed Web of Science ®Google Scholar
• Feliers D, Duraisamy S, Faulkner JL et al. Activation of renal signaling pathways in db/db mice with Type 2 diabetes. Kidney Int.60(2), 495–504 (2001).
   PubMed Web of Science ®Google Scholar
• Stitt TN, Drujan D, Clarke BA et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell.14(3), 395–403 (2004).
   PubMed Web of Science ®Google Scholar
• Galiano RD, Zhao LL, Clemmons DR et al. Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model. J. Clin. Invest.98(11), 2462–2468 (1996).
   PubMed Web of Science ®Google Scholar
• Sakai K, D’Ercole AJ, Murphy LJ et al. Physiological differences in insulin-like growth factor binding protein-1(IGFBP-1) phosphorylation in IGFBP-1 transgenic mice. Diabetes50(1), 32–38 (2001).
   PubMed Web of Science ®Google Scholar
• Gockerman A, Prevette T, Jones JI et al. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology136(10), 4168–4173 (1995).
   PubMed Web of Science ®Google Scholar
• George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. β cell expression of IGF-I leads to recovery from Type 1 diabetes. J. Clin. Invest.109(9), 1153–1163 (2002).
   PubMed Web of Science ®Google Scholar
• Ahn CW, Kim CS, Nam JH, et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese Type 2 diabetic patients with poor glycaemic control. Clin. Endocrinol. (Oxford)64(4), 444–449 (2006).
   Google Scholar
• Pennisi P, Gavrilova O, Setser-Portas J et al. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of Type 2 diabetes mellitus. Endocrinology147(6), 2619–2630 (2006).
   PubMedGoogle Scholar
• Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in Type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J. Clin. Endocrinol. Metab.85(9), 3077–3084 (2000).
   PubMed Web of Science ®Google Scholar